Disease · MONDO_0015760

T-cell non-Hodgkin lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. T-cell non-Hodgkin lymphoma. Diseases, record MONDO_0015760. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015760

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: T-cell non-Hodgkin lymphoma; Open Targets
Open Targets ID: MONDO_0015760; Open Targets
Other names: T cell lymphoma, T-cell NHL, T-cell and NK-cell non-Hodgkin lymphoma, T-cell and NK-cell non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, non-Hodgkin's T-cell lymphoma; Open Targets
Disease Ontology: DOID:0081312; Disease Ontology
MeSH: D016399; MeSH
NCI Thesaurus: C3466; NCI Thesaurus
Orphanet: ORPHA:171918; Orphanet
Highest stage of its drugs: Approval, for 7 of its 73 drugs, from DailyMed and TTD; Open Targets

Drugs73

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ROMIDEPSIN	CHEMBL343448	Protein	Approval	DailyMed	6	5	5	Drugs and targets
VORINOSTAT	CHEMBL98	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
BELINOSTAT	CHEMBL408513	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
PRALATREXATE	CHEMBL1201746	Small molecule	Approval	DailyMed	4	1	1	Drugs and targets
BEXAROTENE	CHEMBL1023	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MECHLORETHAMINE	CHEMBL427	Small molecule	Approval	TTD	1	0	0	Drugs and targets
METHOXSALEN	CHEMBL416	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets

1 to 10 of 73

See all 73 drugs

Targets122

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	6	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
HDAC1	Histone deacetylase	4	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	4	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	4	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	4	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/10013	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	4	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
HDAC10	Histone deacetylase	3	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	3	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC4	Histone deacetylase	3	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	3	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/10014	Drugs and targets

1 to 10 of 122

See all 122 targets

Trials50

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01076543	Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Phase 1/2	110	2019-10-16	AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Waldenstrom Macroglobulinemia	LENALIDOMIDE, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01998035	Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies	Phase 1/2	58	2024-08-22	Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma	AZACITIDINE, ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT02567656	Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma	Phase 1	58	2020-01-13	Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous	TENALISIB	Its record names the disease	ClinicalTrials.gov
NCT00506597	Erwinase Study in Patients With Acute Lymphoblastic Leukemia	Not applicable	33	2014-09-11	Leukemia	CRISANTASPASE	Its record names the disease	ClinicalTrials.gov
NCT03770000	Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma	Phase 1/2	33	2022-10-28	T Cell Lymphoma	ROMIDEPSIN, TENALISIB	Its record names the disease	ClinicalTrials.gov
NCT00069238	Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas	Phase 2	31	2016-01-21	Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell	ALEMTUZUMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, PREDNISONE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00416351	Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment	Phase 1/2	29	2022-05-17	Leukemia, Lymphoma, Small Intestine Cancer	CLOFARABINE	Its record names the disease	ClinicalTrials.gov
NCT02341014	Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas	Phase 1/2	27	2024-04-04	T-cell Lymphomas, Relapsed or Refractory	CARFILZOMIB, LENALIDOMIDE, ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT00798096	Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma	Phase 2	18	2014-06-12	T Cell Lymphoma	FOSTAMATINIB DISODIUM	Its record names the disease	ClinicalTrials.gov
NCT01445535	Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas	Phase 1	15	2020-08-18	T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, PREDNISONE, RITUXIMAB, SIPLIZUMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 50

See all 50 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Phase 1 vs Phase 2: deaths from any cause	11 of 26	0 of 25	51	NCT01998035	Trial comparisons
Phase 1 vs Phase 2: serious adverse events	11 of 26	12 of 25	51	NCT01998035	Trial comparisons
Schedule A: Vorinostat Once or Twice Daily vs Schedule B: Vorinostat Three Times Daily: serious adverse events	8 of 8	5 of 6	14	NCT00787527	Trial comparisons
Schedule A - Vorinostat Once Daily vs Schedule A - Vorinostat Twice Daily: Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat	1 of 6	2 of 2	8	NCT00787527	Trial comparisons
Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: Number of Participants With a Dose-limiting Toxicity (DLT)	1 of 6	1 of 2	8	NCT03905135	Trial comparisons
Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	6 of 6	2 of 2	8	NCT03905135	Trial comparisons
Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: deaths from any cause	3 of 6	0 of 2	8	NCT03905135	Trial comparisons
Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: serious adverse events	6 of 6	0 of 2	8	NCT03905135	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35175355	RESULT	2	PubMed
29032710	RESULT	1	PubMed
42640855	DERIVED	1	PubMed
38886623	DERIVED	1	PubMed
38664936	DERIVED	1	PubMed
37439343	DERIVED	1	PubMed
36898933	DERIVED	1	PubMed
35882475	DERIVED	1	PubMed
34320785	DERIVED	1	PubMed
33883258	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015760

GET https://conductscience.org/api/diseases/v1/MONDO_0015760/drugs?page=2

API reference For AI assistants